Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026)

Merck (MRK) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 6.03% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 6.03% YoY) and the FY2025 annual result came in at $1.4 billion, down 52.91% from the prior year.
• Non-Current Deferred Tax Liability rose to $1.5 billion in Q1 2026 per MRK's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.1 billion in Q1 2022 and bottomed at $864.0 million in Q3 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $1.4 billion (2025), against an average of $1.7 billion.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability jumped 155.07%; it then plunged 66.51% in 2023.
• Tracing MRK's Non-Current Deferred Tax Liability over 5 years: stood at $1.8 billion in 2022, then surged by 64.79% to $3.0 billion in 2023, then climbed by 3.31% to $3.1 billion in 2024, then slumped by 52.91% to $1.4 billion in 2025, then grew by 3.82% to $1.5 billion in 2026.
• Per Business Quant, the three latest MRK Non-Current Deferred Tax Liability figures stand at $1.5 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025).

Peer Comparison